Current Funding Opportunities

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials
The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay. In addition, analytical validation of assays for these markers should be achieved when the application is submitted so that clinical validation may be achieved with little further analytical validation needed. This supplement may be used to support acquisition of specimens from retrospective or prospective studies from NCI-supported or other clinical trials. Clinical laboratory staff, technical and other needs must be an integral part of the application. Assays proposed for this FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials.   

Application Deadline: October 7, 2015

Smoking Cessation within the Context of Lung Cancer Screening
The goal of this Funding Opportunity Announcement (FOA) is to improve the effectiveness and/or implementation of smoking cessation interventions delivered to current smokers who undergo low-dose computed tomography (LDCT) lung cancer screening. The proposed projects must be aimed at determining:
a) the key components and characteristics of an effective smoking cessation intervention delivered in the LDCT setting; and/or
b) characteristics of an implementation strategy to optimally incorporate existing evidence-based smoking cessation intervention(s) into the LDCT setting.

Application Deadline: October 8, 2015

NCI Outstanding Investigator Award (R35)
The NCI is pleased to announce the reissuance of the Outstanding Investigator Award (OIA) funding opportunity announcement: PAR-15-342.  The OIA will support investigators with outstanding records of productivity in cancer research with $600,000 in direct costs per year for 7 years to provide funding stability.  

The OIA will allow funded investigators the freedom to embark on long-term projects of unusual potential in cancer research; the opportunity to take greater risks and be more adventurous in their lines of inquiry; and sufficient time to develop new techniques. 
Applications must be submitted by Institutions who have nominated a Program Director/Principal Investigator (PD/PI) with outstanding productivity in cancer research as a recipient of NCI grant(s) for at least the last 5 consecutive calendar years. The PD/PI will be expected to commit at least 50% of his/her research activities to the OIA; the Institution will be expected to commit at least 20% salary support.  Interested applicants should read the reissuance closely, since there are a few significant changes from the first issuance, including eligibility requirements and research strategy page length.

Letter of Intent due date:  October 23, 2015


The Major Research Instrumentation Program (MRI) serves to increase access to shared scientific and engineering instruments for research and research training in our Nation's institutions of higher education, not-for-profit museums, science centers and scientific/engineering research organizations. The program provides organizations with opportunities to acquire major instrumentation that supports the research and research training goals of the organization and that may be used by other researchers regionally or nationally. 

• The acquisition, through purchase, upgrade, or development of major state-of-the-art instrumentation for research, research training, and integrated research/education activities.
• Proposals may be for a single instrument, or multiple instruments that when combined form an integrated instrument.
• NSF will consider proposals related to NSF-supported fields of science, mathematics, or engineering.  
Limited Submission:  Yale University may submit up to three (3) proposals for the acquisition or development of instrumentation.  

Funding:  Awards will range from $100,000 to $4 million for both acquisition and development proposals. 
                 Applications for less than $100,000 will also be accepted for instrumentation needs within the social, behavioral, and economic sciences.
                 Cost sharing equal to 30% of total proposal project costs is required on all proposals.
                Contributions towards cost-sharing may be made from any non-Federal source, and may be cash or in-kind.  

Internal Deadline: FRIDAY, OCTOBER 23, 2015

NCCN Request for Proposals (RFP): Preclinical Studies of Mirvetuximab Soravtansine for Selected Solid Tumors

The National Comprehensive Cancer Network (NCCN) has received a research grant from ImmunoGen under a Research Agreement dated as of March 6, 2015 (the “Research Agreement”) to support NCCN Member Institution faculty for the performance of preclinical studies with mirvetuximab soravtansine, previously known as IMGN853, in lung, breast, mesothelioma, endometrial, ovarian and gastric cancers. NCCN will serve as the funding organization for these grants that are available only to NCCN investigators. The following details the objectives, process and requirements of this RFP, which shall be

Investigators are asked to submit RFPs detailing proposed research projects.  The overall aim of this RFP is to develop innovative studies of mirvetuximab soravtansine in lung, breast, mesothelioma, endometrial, ovarian and gastric cancers.  Collaborative studies between NCCN Member Institutions are encouraged.   

Deadline for RFPs: By 5:00 PM EDT, Monday, October 26, 2015. 

For additional information, please contact Doreen Walker, Administrative Assistant, Oncology Research Program, at (215) 690-0565 or via email at

Learn More>>

Leslie H. Warner Postdoctoral Fellowships for Cancer Research Awards 2015-2016

Yale Cancer Center announces a competition for The Leslie H. Warner Postdoctoral Fellowships, to be awarded for one year commencing December 1, 2015, to fellows conducting cancer research with a Yale Cancer Center member. The Fellowships will support innovative basic, translational, clinical, or population-based cancer research. Candidates who began postdoctoral studies on or after December 1, 2014 are eligible for this award. Up to four applications will be funded.

The Leslie H. Warner Postdoctoral Fellows will be appointed as postdoctoral associates and will receive an annual salary of up to $43,800, as well as fringe benefits.

Awards will be based on scientific promise of the applicant based on publication record and letters of recommendation, quality of research plan, cancer relevance, and quality of training experience.

Applicants should present a two-page research proposal and a separate abstract clearly indicating the relevance of the proposed research to the field of cancer, a current curriculum vitae, two letters of reference from qualified individuals familiar with the applicant, and a letter from the faculty mentor (three letters total).

Further information may be obtained from Dan DiMaio ( Application materials may be obtained from Jan Zulkeski ( Submit completed applications including a complete, signed PDF to Jan Zulkeski in the Sterling Hall of Medicine, I-141. 

Application Deadline: October 29, 2015 

Women’s Health Research at Yale Pilot Projects Award
Now in its 18th year, Women’s Health Research at Yale has provided $4.8 million in Pilot Project Program funding, and the results of these seed grants to Yale researchers have generated more than $61 million in new external funding for Yale laboratories and clinical research settings.  

All studies selected for funding must demonstrate innovative approaches to understanding women’s health or sex differences, and describe a clear path to implementation for clinical or public health benefit. The projects funded by Women’s Health Research at Yale span a wide array of research topics on gender-related health conditions.  For a list of topics, please visit the Research section of our website -

Full-time Yale Ladder Faculty are eligible to apply. Investigators outside the Yale community are invited to collaborate with Yale or Yale-affiliated principal investigators.

Letters of Intent are due: Thursday, October 29, 2015 (noon)

The Wendy U. & Thomas C. Naratil Pioneer Award 
All studies selected for funding must demonstrate innovative approaches to understanding women’s health or sex differences, and describe a clear path to implementation for clinical or public health benefit. The projects funded by Women’s Health Research at Yale span a wide array of research topics on gender-related health conditions. For a list of topics, please visit the Research section of our website -

Full-time Yale Ladder Faculty are eligible to apply. Investigators outside the Yale community are invited to collaborate with Yale or Yale-affiliated principal investigators.

Letters of Intent are due: Thursday, October 29, 2015 (noon)

Learn More>>

Tina Brozman Foundation 2015 Ovarian Cancer Research Pilot
To provide funding for a pilot project in ovarian cancer prevention and early detection, which would ultimately lead to national peer-reviewed grants.

The research proposal should not exceed three (3) pages, single-spaced (12 point font), with a description of aims, procedures and methods, background, and preliminary data if any. Include a timeline for the proposed research.  References may exceed the 5-page limit.  The application should clearly state how the research relates to ovarian cancer prevention and early detection. Applications that do not conform to the intent of this grant program will not be reviewed.

SUBMISSION:  One PDF file of the complete application should be emailed to Donna Cropley ( by the deadline. Incomplete applications or those received after the deadline will not be considered. For Additional Information: Please contact

Application Deadline: Friday, October 30, 2015

Learn More>>

Grants for Small Projects to Improve Patient Care
Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven are pleased to announce the second call for applications to fund small projects to improve patient care at Smilow Cancer Hospital. Monies for this program have come through our “Closer to Free” fund.  Any employee at Smilow Cancer Hospital who develops a small project may apply by submitting an application for review. Projects can range from a patient education program to stress management for staff.  In order to be eligible, the employee must be sponsored by a current Cancer Center Member. A listing of active cancer center members is on the web site. 

Amount: $2,500 to $5,000 each
Eligibility: Employees of Smilow Cancer Hospital at Yale-New Haven and Care Centers
Sponsorship: Member of Yale Cancer Center
Application: Limited to 3 pages, typed, double spaced; plus budget with justification   (3 copies)
Application sheet: Project Due Date November 2, 2015
  • Project Description, including an evaluation plan
  • Budget 
  • Budget Justification

Submit to Renee Gaudette:
For questions, contact Dr. Ruth McCorkle by email:

Application Deadline: November 2, 2015.

Melanoma Research Alliance Grants

The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for high-impact translational research that has the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment. This cycle, proposals will be accepted for Team Science Awards, Young Investigator Awards, Academic-Industry Partnership Awards (for Established Investigators), and Special Opportunity Awards. Team Science Letter of Intent Due: October 12, 2015 Young Investigator Award and Academic-Industry Partnership

Proposals Due:

November 16, 2015

Learn More>>

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) 
This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.  

Application Due Date: Application Receipt/Submission Date(s): February 17, 2016; August 16, 2016; February 15, 2017; August 15, 2017; February 15, 2018; August 15, 2018, by 5:00 PM local time of applicant organization.